(Q35192266)

7 August 2017

1 reference

title

Flt3 mutations and leukaemia (English)

1 reference

7 August 2017

1 reference

3

David C Linch

1 reference

7 August 2017

2

Rosemary E Gale

1 reference

7 August 2017

author name string

Panagiotis D Kottaridis

series ordinal

1

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

British Journal of Haematology

7 August 2017

published in

1 reference

7 August 2017

volume

122

1 reference

7 August 2017

issue

4

1 reference

7 August 2017

page(s)

523-538

1 reference

Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia

7 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?--an adult treater's view

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Cooperativity between mutations in tyrosine kinases and in hematopoietic transcription factors in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

The roles of FLT3 in hematopoiesis and leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibit

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

CXCR4-SDF-1 signaling is active in rhabdomyosarcoma cells and regulates locomotion, chemotaxis, and adhesion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Biology of flt3 ligand and receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Stable remission after administration of the receptor tyrosine kinase inhibitor SU5416 in a patient with refractory acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Molecular evolution of acute myeloid leukaemia in relapse: unstable N-ras and FLT3 genes compared with p53 gene.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

The partial tandem duplication of ALL1 (MLL) is consistently generated by Alu-mediated homologous recombination in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

All-trans-retinoic acid in acute promyelocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Bis(1H-2-indolyl)-1-methanones as inhibitors of the hematopoietic tyrosine kinase Flt3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2141.2003.04500.X

10.1046/J.1365-2141.2003.04500.X

21 January 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference